- Email: [email protected]
Activation of platelet function ex vivo and in vivo in diabetic patients
Suppl. XIII, 1991
ABSTRACTS
21
41
ACTIVATION OF PLATELET FUNCTION EX VZVO AND IN WV0 IN DIABETIC PATIENTS. L. Tomaselli, C. Cerletti, M. Pupillo *, G. de Gaetano. Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro; *Ospedale Civile “F.Renzetti”, Lanciano. To compare ex vivo and in vivo platelet function in diabetes we studied 5 healthy volunteers and 7 insulin-treated diabetic patients (3 non insulin-dependent, 4 insulin-dependent) with macro and/or microvascular complications (duration of diabetes: 19.8k3.0 years; HbAl 10.7zhl.O %). Both ex vivo and in vivo studies were performed in all subjects: 1. Platelet aggregation response to sodium arachidonate and serum TxB2 after spontaneous blood clotting at 37’C; 2. l l-dehydro-TxB2 urinary excretion. Platelet capacity to generate TxA2 ex vivo as well as platelet aggregation were similar in diabetic patients and healthy subjects. In contrast, the urinary excretion of 11-dehydro-TxB2 was significantly higher in patients than in controls (113.943 1.2 vs 49.6k9.4 rig/h,, ~~0.002). Administration of a cyclooxygenase inhibitor (indobufen, 200 mg b.i.d. for 7 days) to patients resulted in a marked reduction of 1I-dehydro-TxB2 excretion (19.6k12.4 rig/h). The discrepancy between ex vivo and in vivo platelet function suggests that in diabetic patients with vascular complications platelets are essentially normal in a test tube, being activated by interaction with damaged vascular walls. Pharmacological decrease of in vivo platelet TxA2 synthesis might be of therapeutic relevance, since platelets activation may contribute to the evolution of diabetic vascular complications.
42 INSULIN THERAPY MODULATES IN VIVO THROMBIN ACTINTRAPERITONEAL IN INSULIN-DEPENDENT (TYPE I) DIABETICS. A.D'Angelo, P. IVITY E.Orsi, S.Testa, S.Vigano'D'Angelo, G.Pozza. Servizio Micossi, Istituto Scientidi Coagulazione e Cattedra di Clinica Medica, fico H.S.Raffaele, Milano, Italy. ten A series of coagulation parameters was evaluated in patients with poorly controlled insulin-dependent diabetes (IDD) during intensive SC insulin but free of vascular complications, after implantation of a Programmtherapy and 1, 2, and 3 months able Insulin Infusion Pump (Model 1000 Infusaid,Norwood,MA,USA), connected to an intraperitoneal catheter. Elevated plasma levels of von Willebrand factor (vWF:Ag, p
ABSTRACTS
21
41
ACTIVATION OF PLATELET FUNCTION EX VZVO AND IN WV0 IN DIABETIC PATIENTS. L. Tomaselli, C. Cerletti, M. Pupillo *, G. de Gaetano. Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro; *Ospedale Civile “F.Renzetti”, Lanciano. To compare ex vivo and in vivo platelet function in diabetes we studied 5 healthy volunteers and 7 insulin-treated diabetic patients (3 non insulin-dependent, 4 insulin-dependent) with macro and/or microvascular complications (duration of diabetes: 19.8k3.0 years; HbAl 10.7zhl.O %). Both ex vivo and in vivo studies were performed in all subjects: 1. Platelet aggregation response to sodium arachidonate and serum TxB2 after spontaneous blood clotting at 37’C; 2. l l-dehydro-TxB2 urinary excretion. Platelet capacity to generate TxA2 ex vivo as well as platelet aggregation were similar in diabetic patients and healthy subjects. In contrast, the urinary excretion of 11-dehydro-TxB2 was significantly higher in patients than in controls (113.943 1.2 vs 49.6k9.4 rig/h,, ~~0.002). Administration of a cyclooxygenase inhibitor (indobufen, 200 mg b.i.d. for 7 days) to patients resulted in a marked reduction of 1I-dehydro-TxB2 excretion (19.6k12.4 rig/h). The discrepancy between ex vivo and in vivo platelet function suggests that in diabetic patients with vascular complications platelets are essentially normal in a test tube, being activated by interaction with damaged vascular walls. Pharmacological decrease of in vivo platelet TxA2 synthesis might be of therapeutic relevance, since platelets activation may contribute to the evolution of diabetic vascular complications.
42 INSULIN THERAPY MODULATES IN VIVO THROMBIN ACTINTRAPERITONEAL IN INSULIN-DEPENDENT (TYPE I) DIABETICS. A.D'Angelo, P. IVITY E.Orsi, S.Testa, S.Vigano'D'Angelo, G.Pozza. Servizio Micossi, Istituto Scientidi Coagulazione e Cattedra di Clinica Medica, fico H.S.Raffaele, Milano, Italy. ten A series of coagulation parameters was evaluated in patients with poorly controlled insulin-dependent diabetes (IDD) during intensive SC insulin but free of vascular complications, after implantation of a Programmtherapy and 1, 2, and 3 months able Insulin Infusion Pump (Model 1000 Infusaid,Norwood,MA,USA), connected to an intraperitoneal catheter. Elevated plasma levels of von Willebrand factor (vWF:Ag, p